ES2096867T3 - Uso de antagonistas competitivos del receptor de nmda en el tratamiento de la incontinencia urinaria. - Google Patents
Uso de antagonistas competitivos del receptor de nmda en el tratamiento de la incontinencia urinaria.Info
- Publication number
- ES2096867T3 ES2096867T3 ES93305762T ES93305762T ES2096867T3 ES 2096867 T3 ES2096867 T3 ES 2096867T3 ES 93305762 T ES93305762 T ES 93305762T ES 93305762 T ES93305762 T ES 93305762T ES 2096867 T3 ES2096867 T3 ES 2096867T3
- Authority
- ES
- Spain
- Prior art keywords
- urinary incontinence
- treatment
- nmda receptor
- competitive antagonists
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
LA PRESENTE INVENCION PROVEE UN METODO DE TRATAR INCONTINENCIA URINARIA DE IMPULSO MOTOR EN UN MAMIFERO LA CUAL COMPRENDE ADMINISTRAR UNA CANTIDAD EFECTIVA DE UN ANTAGONISTA NMDA COMPETITIVO, TAL COMO ACIDO (3S,4AR,6S,8AR) FONIOMETILO) 3 8AR) ISOQUINOLINACARBOXILICO, O ACIDO (2R, 4S)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/919,480 US5192751A (en) | 1992-07-24 | 1992-07-24 | Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2096867T3 true ES2096867T3 (es) | 1997-03-16 |
Family
ID=25442169
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES93305762T Expired - Lifetime ES2096867T3 (es) | 1992-07-24 | 1993-07-22 | Uso de antagonistas competitivos del receptor de nmda en el tratamiento de la incontinencia urinaria. |
Country Status (9)
Country | Link |
---|---|
US (1) | US5192751A (es) |
EP (1) | EP0580429B1 (es) |
JP (1) | JPH06183975A (es) |
AT (1) | ATE147977T1 (es) |
CA (1) | CA2100950A1 (es) |
DE (1) | DE69307617T2 (es) |
DK (1) | DK0580429T3 (es) |
ES (1) | ES2096867T3 (es) |
GR (1) | GR3023032T3 (es) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5594007A (en) * | 1991-04-18 | 1997-01-14 | Pfizer Inc. | Method for treating spinal cord trauma with phenolic 2-piperidino-1-alkanols |
US5436255A (en) * | 1992-07-23 | 1995-07-25 | Pfizer Inc. | Method of treating diseases susceptable to treatment by blocking NMDA-receptors |
US5192751A (en) * | 1992-07-24 | 1993-03-09 | Eli Lilly And Company | Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence |
US5284957A (en) * | 1992-09-03 | 1994-02-08 | Eli Lilly And Company | Excitatory amino acid receptor antagonists |
US5498610A (en) * | 1992-11-06 | 1996-03-12 | Pfizer Inc. | Neuroprotective indolone and related derivatives |
TW344661B (en) * | 1993-11-24 | 1998-11-11 | Lilly Co Eli | Pharmaceutical composition for treatment of incontinence |
DE69420053T2 (de) * | 1994-01-31 | 1999-11-25 | Pfizer | Neuroprotektive chroman verbindungen |
HUT77520A (hu) * | 1994-08-18 | 1998-05-28 | Pfizer Inc. | Neuroprotektív hatású kromán-4,7-diol- és 1-(4-hidroxifenil)-alkanol-származékok és azokat hatóanyagként tartalmazó gyógyszerkészítmények |
EP0820288B1 (en) * | 1995-03-03 | 2004-02-11 | Endo Pharmaceuticals Inc. | Use of dextromethorphan or dextrorphan for the treatment of urinary incontinence |
ZA9610745B (en) * | 1995-12-22 | 1997-06-24 | Warner Lambert Co | 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists |
ZA9610741B (en) | 1995-12-22 | 1997-06-24 | Warner Lambert Co | 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists |
ZA9610736B (en) * | 1995-12-22 | 1997-06-27 | Warner Lambert Co | 2-Substituted piperidine analogs and their use as subtypeselective nmda receptor antagonists |
ZA9610738B (en) * | 1995-12-22 | 1997-06-24 | Warner Lambert Co | Subtype selective nmda receptor ligands and the use thereof |
TW427978B (en) * | 1996-02-03 | 2001-04-01 | Hoffmann La Roche | Tetrahydroisoquinoline derivatives |
US5880138A (en) * | 1996-10-01 | 1999-03-09 | Eli Lilly And Company | NMDA receptor selective antagonists |
US7455845B2 (en) | 1997-07-15 | 2008-11-25 | The Regents Of The University Of Colorado | Use of neurotoxin therapy for treatment of urologic and related disorders related to lowering elevated bladder pressure |
US7449192B2 (en) | 1997-07-15 | 2008-11-11 | The Regents Of The University Of Colorado | Use of neurotoxin therapy for treatment of urologic and related disorders related to neurogenic bladder dysfunction |
US7470431B2 (en) | 1997-07-15 | 2008-12-30 | The Regents Of The University Of Colorado | Use of neurotoxin therapy for treatment of urological-neurological disorders associated with prostate cancer |
US9066943B2 (en) | 1997-07-15 | 2015-06-30 | The Regents Of The University Of Colorado | Use of botulinum toxin therapy for treatment of urological neurological conditions |
DE69835911T3 (de) | 1997-07-15 | 2011-01-13 | The Regents Of The University Of Colorado, Boulder | Verwendung einer Neurotoxintherapie zur Behandlung der Harnverhaltung |
PE20000728A1 (es) | 1998-06-26 | 2000-08-21 | Cocensys Inc | Heterociclos 4-bencil piperidina alquilsulfoxido y su uso como antagonistas receptores subtipo-selectivo nmda |
PT1196172E (pt) * | 1999-07-01 | 2006-05-31 | Pharmacia & Upjohn Co Llc | (s,s)-reboxetina para tratar a dor cronica |
US7375136B2 (en) * | 2001-03-08 | 2008-05-20 | Emory University | pH-dependent NMDA receptor antagonists |
AU2008272964A1 (en) | 2007-06-29 | 2009-01-08 | Emory University | NMDA receptor antagonists for neuroprotection |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4968678A (en) * | 1988-02-19 | 1990-11-06 | Eli Lilly And Company | Tetrazole excitatory amino acid receptor antagonists |
US4902695A (en) * | 1989-02-13 | 1990-02-20 | Eli Lilly And Company | Excitatory amino acid receptor antagonists |
US5192751A (en) * | 1992-07-24 | 1993-03-09 | Eli Lilly And Company | Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence |
-
1992
- 1992-07-24 US US07/919,480 patent/US5192751A/en not_active Expired - Fee Related
-
1993
- 1993-07-20 CA CA002100950A patent/CA2100950A1/en not_active Abandoned
- 1993-07-22 EP EP93305762A patent/EP0580429B1/en not_active Expired - Lifetime
- 1993-07-22 DE DE69307617T patent/DE69307617T2/de not_active Expired - Fee Related
- 1993-07-22 ES ES93305762T patent/ES2096867T3/es not_active Expired - Lifetime
- 1993-07-22 DK DK93305762.2T patent/DK0580429T3/da active
- 1993-07-22 AT AT93305762T patent/ATE147977T1/de active
- 1993-07-23 JP JP5182731A patent/JPH06183975A/ja active Pending
-
1997
- 1997-04-03 GR GR970400699T patent/GR3023032T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
US5192751A (en) | 1993-03-09 |
EP0580429A1 (en) | 1994-01-26 |
DK0580429T3 (da) | 1997-07-14 |
JPH06183975A (ja) | 1994-07-05 |
ATE147977T1 (de) | 1997-02-15 |
GR3023032T3 (en) | 1997-07-30 |
DE69307617T2 (de) | 1997-05-28 |
DE69307617D1 (de) | 1997-03-06 |
EP0580429B1 (en) | 1997-01-22 |
CA2100950A1 (en) | 1994-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2096867T3 (es) | Uso de antagonistas competitivos del receptor de nmda en el tratamiento de la incontinencia urinaria. | |
NL300174I1 (nl) | Toepassing van venlafaxine of een aryloxypropaanamineverbinding voor de bereiding van een geneesmiddel voor de behandeling van incontinentie. | |
ES2115691T3 (es) | Derivados de benzotiepina, benzotiopirano y benzotiofeno, su obtencion y utilizacion de los mismos como farmacos. | |
ATE154880T1 (de) | Multifunktionelle pharmazeutische verbindungen und verfahren zu ihrer verwendung | |
CL2003002756A1 (es) | Compuestos derivados de (1-carbamoil-1,1-defenilmetil)-1-[substituido)alquil]purrolidinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del sindrome de intestino irritable o incontinencia. | |
MX9200361A (es) | Nuevo uso del antagonista de adenosina. | |
FI921345A (fi) | Piperidinderivat | |
ES2133324T3 (es) | Compuestos de dibenzoxazepina sustituidos, composiciones farmaceuticas y metodos de uso. | |
DE69223736T2 (de) | Acridine-1,8-Dionderivate als therapeutisches Mittel | |
DE69330754T2 (de) | 2,5-DIOXO-2,5-DIHYDRO-1H-BENZ[b]AZEPINE ALS NMDA REZEPTOR ANTAGONISTEN | |
ATE161531T1 (de) | Acridine-1,8-dionderivate als therapeutisches mittel | |
HU9700661D0 (en) | Use of alpha-1-adrenoreceptor antagonists for profilacting and treating cancer | |
ES2113345T3 (es) | Tratamiento de la disfuncion cardiaca con la ayuda de compuestos 15-ceto-prostaglandina. | |
ATE145911T1 (de) | Inositol-phosphat-analog als kalzium- antagonistische substanz | |
WO1992007564A3 (en) | Method of treating demyelinating disease | |
DE69009765D1 (de) | Kynurensäurederivate, deren herstellung und diese enthaltende pharmazeutische zusammensetzungen. | |
ES2097277T3 (es) | Uso de un compuesto ester tiol-s-(2-dietilaminoetilico) para la preparacion de un medicamento para el tratamiento de la incontinencia neuro-muscular. | |
GR3020597T3 (en) | Phospholipids for the treatment of multiple sclerosis | |
IT217652Z2 (it) | Dispositivo di sicurezza per l'arresto, particolarmente di ascensori. | |
ITRM920516A1 (it) | Composizione e suo uso per il trattamento terapeutico di affezioni dermatitiche, particolarmente la psoriasi. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 580429 Country of ref document: ES |